Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

27.580
+1.2404.71%
Volume:7.45M
Turnover:204.62M
Market Cap:9.76B
PE:-30.99
High:28.200
Open:27.800
Low:27.020
Close:26.340
52wk High:60.100
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:1.54
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:1.59
PE(LYR):-30.99
PS:3.46

Loading ...

Movement Alert|EVEREST MED Rises 5.24% in Regular Trading, Drug Registration Application for Domestic Production Transfer of Weishiping Accepted

Market Focus
·
Sep 18

Hong Kong Stock Market Alert: EVEREST MED Surges Over 5% on Regulatory Filing Acceptance for Local Production Transfer

Stock News
·
Sep 18

Everest Medicines Chairman Wu Yifang Boosts Stake With New Share Purchase at HK$28.71 Each

Deep News
·
Sep 13

Board Chairman Acquires Additional Stake in EVEREST MED with Two-Thousand-Share Purchase

Stock News
·
Sep 11

EVEREST MED: Yifang Wu Acquires Shares, Long Position Rises to 0.62%

HK Disclosure
·
Sep 11

Movement Alert|EVEREST MED Falls 5.39% in Regular Trading, Haisen Strategic Cooperation Raises Related-Party Transaction Concerns Amid Continued Profit-Taking

Market Focus
·
Sep 11

Movement Alert|EVEREST MED Falls 5.38% in Regular Trading, Post-Approval Profit-Taking on Xingbituo Continues Amid Sector Weakness

Market Focus
·
Sep 10

Everest Medicines Unit Enters Supply, Distribution Cooperation Contract

MT Newswires Live
·
Sep 09

Everest Medicines seals strategic cooperation with Hasten; sets RMB3.08 billion 2028 cap on connected transactions

Bulletin Express
·
Sep 09

Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion

Stock News
·
Sep 09

Movement Alert|EVEREST MED Falls 5.02% in Regular Trading, Post-Approval Rally Fades as Xingbituo PSVT Milestone Fully Priced In

Market Focus
·
Sep 09

Hong Kong Stock Market Flash | EVEREST MED Surges Over 5% in Morning Trade as China Approves NDA for PSVT Indication

Stock News
·
Sep 08

Movement Alert|EVEREST MED Rises 5.05% in Regular Trading, First Cardiovascular Drug Star Bi Tuo Approved by NMPA

Market Focus
·
Sep 08

Everest Med Lifts Issued Share Count to 354.08 Million in August on Option Exercises

Bulletin Express
·
Sep 04

Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment to the Co

Reuters
·
Sep 03

Everest Medicines Gets China Nod for CARDAMYST Application

MT Newswires Live
·
Sep 03

EVEREST MED Wins NMPA Approval for CARDAMYST Nasal Spray, First Self-Administered Treatment for Adult PSVT in China

Bulletin Express
·
Sep 03

Everest Medicines Says China NMPA Approves Cardamyst Nasal Spray for PSVT Conversion in Adults

Reuters
·
Sep 03

Everest Medicines - Nmpa Approves Cardamyst (Etripamil) Nda for Psvt in Adults in China

THOMSON REUTERS
·
Sep 03

EVEREST MED's pioneering cardiovascular treatment receives green light in China, introducing the first and only on-demand rescue therapy for adults with PSVT

Stock News
·
Sep 03